DexCom will work with Google’s life sciences team to jointly develop a series of next-generation continuous glucose monitoring (CGM) products that are designed to be smaller and less expensive than existing technologies. The magic will happen by combining Google’s miniaturized electronics platform with DexCom’s sensor technology.
“This partnership has the potential to change the face of diabetes technology forever,” said Kevin Sayer, President and CEO of DexCom. “Working together, we believe we can introduce products that will move us beyond our core Type 1 business to become the standard of care for all people living with diabetes.”
Also, the collaboration provides an opportunity to better utilize the data generated by these CGM products to significantly improve the outcomes and reduce the costs associated with diabetes care.
Initial products will focus on minimizing both the cost and size of CGM body worn components. They will be disposable, and intended for use across all diabetes markets. The goal is to empower more people to control their diabetes with real-time and actionable information by developing a low-cost, small, bandage-sized sensor that is connected to the cloud. By addressing these needs, Google and DexCom hope to replace finger sticks and become the standard of care.
Initial products will focus on minimizing the cost and size of CGM body worn components.“We’re committed to developing new technologies that will help move health care from reactive to proactive,” said Andrew Conrad, head of the life sciences team at Google. “This collaboration is another step towards expanding monitoring options and making it easier for people with diabetes to proactively manage their health.”
DexCom will retain all sales and distribution rights of the products developed under this agreement. However, DexCom will have to pay an initial upfront payment and milestone payments during development, as well as revenue-based royalties once these products are launched and have achieved a certain level of revenue.